SAN DIEGO – May 8, 2026
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company focused on oncology and rare diseases, announced it will present interim clinical data from the randomized Phase 2 portion of its HexAgon study evaluating INBRX-106 in first-line head and neck cancer patients. The company will host a live webcast presentation on May 11, 2026, highlighting emerging safety and efficacy findings for the investigational therapy in patients with PD-L1 positive metastatic or unresectable recurrent Head and Neck Squamous Cell Carcinoma (HNSCC).
The update marks an important milestone for Inhibrx as competition intensifies in the rapidly evolving immuno-oncology market. Industry analysts are closely monitoring therapies targeting OX40 (CD134), a key T-cell costimulatory receptor that has gained significant attention as a potential strategy for enhancing anti-tumor immune responses and improving checkpoint inhibitor outcomes.
INBRX-106 Combines OX40 Activation With Pembrolizumab
The ongoing HexAgon study is evaluating the safety and efficacy of INBRX-106, a novel hexavalent OX40 agonist, in combination with pembrolizumab compared with pembrolizumab monotherapy in treatment-naïve HNSCC patients. The trial specifically targets patients with PD-L1 positive tumors and Combined Positive Score (CPS) ≥20, a patient population commonly treated with immunotherapy-based regimens.
INBRX-106 was developed using Inhibrx’s proprietary single-domain antibody (sdAb) platform, which is designed to achieve high-order receptor clustering necessary for stronger T-cell activation and immune system stimulation. According to the company, traditional bivalent antibody approaches have historically struggled to achieve the level of receptor activation required for robust anti-tumor immune responses.
Advertisement
By utilizing a hexavalent molecular format, INBRX-106 is engineered to provide more potent activation of OX40 signaling pathways, potentially enhancing T-cell proliferation, survival and anti-cancer activity. The combination with pembrolizumab, a widely used PD-1 checkpoint inhibitor, is intended to amplify immune-mediated tumor destruction while overcoming resistance mechanisms commonly observed in advanced head and neck cancers.
Head and Neck Squamous Cell Carcinoma remains one of the most difficult-to-treat solid tumors globally, particularly in patients with recurrent or metastatic disease. Despite advances in immunotherapy, long-term survival rates remain limited for many patients, creating significant demand for next-generation immune-activating therapies capable of improving response durability and clinical outcomes.
Immuno-Oncology Focus Drives Inhibrx Pipeline Expansion
Inhibrx Biosciences continues expanding its pipeline of engineered biologic therapeutics designed to address complex disease biology through advanced protein engineering approaches. The company’s platform technologies focus on optimizing molecular valency and receptor engagement to improve therapeutic activity in oncology and rare disease indications.
The company noted that both INBRX-106 and its additional pipeline candidate ozekibart utilize multivalent therapeutic formats specifically engineered to optimize agonist function in a target-centric manner. Inhibrx believes this strategy may improve efficacy compared with conventional antibody therapies by enhancing receptor clustering and downstream immune signaling pathways.
The webcast presentation is expected to provide investors and oncology researchers with updated clinical insights into the performance of INBRX-106 in first-line HNSCC patients. Market observers are particularly interested in evaluating whether the investigational therapy demonstrates improved response rates, durability and safety relative to standard checkpoint inhibitor monotherapy approaches.
Competitive Landscape in HNSCC Continues Evolving
The global head and neck cancer therapeutics market has become increasingly competitive as pharmaceutical companies invest heavily in immuno-oncology combinations and next-generation immune modulators. OX40 agonists are considered one of several promising strategies being explored to enhance T-cell activation and overcome immune suppression within the tumor microenvironment.
If clinical results continue demonstrating encouraging activity, INBRX-106 could position Inhibrx as a significant emerging player in the immuno-oncology sector. The company’s focus on multivalent biologics and novel receptor-targeting approaches reflects broader industry efforts to develop more effective and durable cancer immunotherapies for patients with difficult-to-treat solid tumors.
Source: Inhibrx Biosciences press release
